Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Capital Expenditures (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Capital Expenditures for 6 consecutive years, with $107000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 79.14% to $107000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $310000.0 through Dec 2025, down 73.11% year-over-year, with the annual reading at $310000.0 for FY2025, 73.11% down from the prior year.
  • Capital Expenditures hit $107000.0 in Q4 2025 for Harmony Biosciences Holdings, up from $71000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $632000.0 in Q2 2024 to a low of $3000.0 in Q3 2024.
  • Historically, Capital Expenditures has averaged $136000.0 across 5 years, with a median of $86000.0 in 2022.
  • Biggest YoY gain for Capital Expenditures was 2460.0% in 2025; the steepest drop was 99.37% in 2025.
  • Year by year, Capital Expenditures stood at $93000.0 in 2021, then fell by 7.53% to $86000.0 in 2022, then increased by 24.42% to $107000.0 in 2023, then surged by 379.44% to $513000.0 in 2024, then crashed by 79.14% to $107000.0 in 2025.
  • Business Quant data shows Capital Expenditures for HRMY at $107000.0 in Q4 2025, $71000.0 in Q3 2025, and $4000.0 in Q2 2025.